This review highlights the rapid evolution and implementation of prostate-specific membrane antigen (PSMA)-directed applications in prostate cancer management.
Despite their growing use, the prognostic implications of PSMA-PET are not yet fully understood due to a lack of long-term follow-up data. Available evidence indicates that high PSMA expression is linked to poorer survival outcomes in localized and biochemically recurrent disease.
PSMA-positive metastases often indicate a higher likelihood of treatment failure. Conversely, low PSMA-PET uptake is generally a favourable prognostic factor.
The review calls for clinical trials to validate PSMA-PET’s role in guiding prostate cancer management with reliable oncological outcomes.
